1Department of Physiology and Biophysics and 2Animal Resource Center, The University of Texas Medical Branch, Galveston, Texas 77555-0641
Submitted 13 October 2003 ; accepted in final form 2 February 2004
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
sodium-phosphate cotransport; uremia
The kidney, small intestine, and bone are the major organs involved in phosphate homeostasis. The intestinal brush-border membrane Na+-phosphate cotransporter (NaPi-IIb) absorbs up to 70% of dietary phosphate. In the serum, phosphate exists as a free ion and calcium salt. The kidney proximal tubule reabsorbs 70% of the filtered phosphate, and the distal kidney reabsorbs 20% (43, 49).
In addition to NaPi-IIb, the NaPi family of proteins includes two renal Na+-phosphate cotransporters, NaPi-IIa and NaPi-Ia, and the ubiquitous Na+-phosphate cotransporters PiT-1 and PiT-2. NaPi-IIa and NaPi-Ia are involved in renal tubule phosphate reabsorption. PTH regulation of proximal tubule phosphate reabsorption is well documented. PTH downregulates NaPi-IIa expression in the proximal tubule brush-border membrane, inducing phosphaturia (41). In renal failure, PTH receptors become unresponsive to PTH by elevated serum PTH concentrations (7, 31, 50, 51). The mechanism of proximal tubule PTH insensitivity in chronic renal failure is not completely understood.
Phosphophloretins have been shown to be effective inhibitors of small intestine brush-border membrane (37, 38) and renal brush-border membrane (39) Na+-phosphate cotransport in isolated brush-border membrane vesicles (BBMV) in vitro. The water-soluble phosphophloretin derivative 2'-phosphophloretin (2'-PP) inhibited Na+-dependent phosphate uptake into intestinal BBMV with an IC50 of 40 nM. 2'-PP inhibited NaPi-Ia transport of phosphate with an IC50 of 50 nM in renal cortex BBMV and distal tubule-enriched apical membrane vesicles (39). An alkylated phosphophloretin (2'-phospho-4',4,6' trimethoxyphloretin) inhibited NaPi-IIa-mediated, Na+-dependent phosphate uptake into renal cortex BBMV and proximal tubule-enriched BBMV with an IC50 of 23 nM (39). In vivo, 2'-PP reduced serum phosphate in adult rats with an IC50 of 10 µM.
Five-sixth nephrectomy rats (5/6 NX) are a well-established and -documented renal failure model system. As a function of time postsurgery and dependent on the postsurgery Ca2+ and phosphorus dietary content, 5/6 NX rats develop renal failure. Many of the serum and systemic complications of chronic renal failure in humans are also seen in the 5/6 NX rat model, including hyperphosphatemia and secondary hyperparathyroidism. We have examined the effect of 2'-PP on serum phosphate, serum PTH, and multiple measures of renal function in 5/6 NX rats with chronic renal failure. In 5-wk experiments, 2'-PP reduced serum phosphate and serum PTH and increased creatinine clearance to levels consistent with moderate to early renal failure. The results indicate that inhibition of intestinal phosphate absorption reduced serum phosphate and serum PTH without altering dietary protein absorption, that 2'-PP treatment improved renal function and reduced serum phosphate, and that reduced serum PTH does not reverse renal hypertrophy but may slow the progressive loss of renal function in the remnant kidney model.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Animals. Eight-week-old male Sprague-Dawley 5/6 NX and age-matched control rats with normal renal function were purchased postsurgery from Charles River Laboratories. Briefly, rats were anesthetized with ketamine/diazepam, and the right kidney was removed. One week later, two-thirds of the left kidney were removed. The animals were allowed to recover for 1 wk. The second week postsurgery, animals were randomly divided into three groups of eight rats, marked, weighed, and housed individually. During a 2-wk acclimation period, animals were placed on a 3-h feeding window and a 12:12-h light-dark cycle. The animals were fed normal rat chow (Teklab 7201) containing 19% protein, 0.67 g/0.1 kg phosphorus, and 0.97 g/0.1 kg calcium and had unlimited access to water.
The handling, treatment, and experiments involving animals were submitted for approval to, examined by, and approved by the UTMB Institutional Animal Care and Use Committee and were in compliance with the American Physiological Society's Guiding Principles in the Care and Use of Animals.
Rats were gavaged daily with vehicle (150 mM NaCl and 5 mM citrate buffer, pH 6) or vehicle plus 25 µM 2'-PP. Blood was withdrawn from the saphenous vein twice a week (14). Collected blood was allowed to clot, and serum was collected by centrifugation for 20 min in a microfuge. Sera were carefully removed and stored on ice. Once a week, rats were placed in metabolic cages for 24-h fecal and urine collection. The animals were weighed once a week immediately before blood was drawn. Each experimental treatment with 2'-PP was 5 wk long. During the course of these studies, none of the rats died during the acclimation and experimental treatment period (2-mo total experimental period).
At the beginning of the treatment period, 5/6 NX rat weights were not significantly different from the weights of age-matched control rats: 326 ± 17 g (n = 48) for 5/6 NX rats and 324 ± 8 g (n = 8) for age-matched control rats. At the end of the 5-wk experiment, untreated 5/6 NX rats weighed 301 ± 13 g (n = 16), 2'-PP-treated rats weighed 360 ± 14 g (n = 26), and age-matched control rats weighed 372 ± 16 g (n = 8).
Serum and urine chemistry. Serum and urine phosphate concentrations were determined spectrophotometrically at 340 nm using clinical phosphorus kits. Standard curves for phosphate were generated using 1, 5, and 10 mg/dl phosphorus standards. Serum and urine calcium were determined spectrophotometrically using the arsenazo dye method (32). Calcium at 5, 10, and 15 mg/dl were used as standards. Serum and urine creatinine were determined by the method of Jaffe (13). Serum protein was determined by the method of Lowry (40) using BSA as a standard. For urine protein determinations, a 2-ml aliquot of urine protein was precipitated with 10% TCA and collected by centrifugation at 3,000 g for 30 min. Precipitated protein was resuspended in 50 mM Tris·HCl, pH 7, and protein concentration was determined (40). Serum intact PTH (i-PTH; 1-84) was determined using an ELISA kit for rat i-PTH without sample freezing.
Urine osmolality was determined using a Precision Systems freezing-point depression osmometer. The osmometer was calibrated using 100, 290, 500, and 1,000 mosmol/kgH2O standards. Ionized Ca2+ was determined using a Ca2+-sensitive electrode, which was calibrated with 100 µM and 1 mM CaCl2.
Fecal chemistry. Feces from untreated uremic control rats and 2'-PP-treated uremic rats were collected once a week in 24-h collections. Total fecal weight was determined, and a 1-g aliquot was processed for the determination of phosphate, calcium, and protein. Fecal specimens were processed in concentrated nitric acid and 70% perchloric acid (15). Phosphate content was determined from the 1-g aliquot using ammonium molybdate at 340 nm multiplied by total fecal weight. Fecal samples for the determination of protein and calcium were processed as described for phosphorus. Calcium was determined using the absorbance of the calcium arsenazo complex at 430 nm. Protein was determined by the method of Lowry using BSA as a standard (40).
Intestinal absorption of phosphate, Ca+, and protein. Intestinal absorption of phosphate was determined using two measures of phosphate absorption. Intestinal absorption was determined as the difference between phosphorus consumed (0.0067 x pellet weight) and fecal phosphorus, or fecal phosphorus normalized to fecal protein. Intestinal absorption of Ca2+ was determined from dietary Ca2+ consumed (0.0097 x pellet weight) minus fecal Ca2+.
Phosphate uptake into intestinal BBMV.
BBMV were isolated from uremic rats and age-matched control rats at the conclusion of the experimental treatment period. Small intestinal BBMV were isolated by Ca2+ precipitation and differential centrifugation (3739). BBMV protein (40) and enrichments of the brush-border membrane enzymes, alkaline phosphatase (9) and -glutamyl transpeptidase (36), were determined. After isolation, BBMV were resuspended in 300 mM mannitol and 10 mM HEPES/Tris, pH 7.5, and stored as aliquots in liquid nitrogen until needed. During the course of these studies, rat intestinal BBMV were 18- to 20-fold enriched in the brush-border membrane markers alkaline phosphatase and
-glutamyl transpeptidase compared with the total homogenate.
Na+-dependent phosphate uptake into intestinal BBMV was performed using a rapid mixing/rapid sampling procedure (3739, 48). Na+-dependent uptake was defined as uptake in the presence of 100 mM NaCl, 100 mM mannitol, 10 mM HEPES/Tris, pH 7.5, and 100 µM [32P]phosphate minus uptake in the presence of 100 mM KCl, 100 mM mannitol, 10 mM HEPES/Tris, pH 7.5, and 100 µM [32P]phosphate. Uptakes were performed for 5 s at 23°C.
In some experiments, the effect of 2'-PP or phloretin on Na+-dependent phosphate uptake into intestinal BBMV was determined. In these experiments, 2'-PP concentration was varied between 5 and 500 nM, and phloretin concentration was varied between 100 nM and 10 µM.
In some experiments, the effect of phosphate concentration on Na+-dependent phosphate uptake and on 2'-PP inhibition of Na+-dependent phosphate uptake into intestinal BBMV was examined. In these experiments, Na+-dependent phosphate uptake was determined as described above. 2'-PP concentration was varied between 5 nM and 1 µM. Phosphate concentration was varied between 10 and 500 µM.
Heart and kidney histology. At the end of the 5-wk experiment, 2'-PP-treated and untreated uremic control rats were killed. Hearts were perfused with 250 mM sucrose, 1 mM EDTA, and 10 mM Tris·HCl, pH 7, and weighed. The left ventricle was removed and weighed. Tissue was fixed in 10% buffered formalin. Cardiac sections were examined by a pathologist who was not aware of which sections corresponded to treatment and control.
Remnant kidneys were removed and weighed. The remnant kidneys were added to 10 ml of 10% buffered formalin and stored at 4°C for 12 h. The formalin was then removed and replaced with fresh 10% buffered formalin. Paraffin sections (4 µm) were stained with hematoxylin and eosin or periodic acid-Schiff (PAS). For each experimental group, multiple sections (1220 sections/animal) from two animals were selected randomly. Renal sections were coded and then examined by a pathologist who was blinded to which sections corresponded to which number.
Synthesis of 2'-PP.
2'-PP was synthesized from phloridzin and dibenzylphosphite in N,N-dimethylacetamide (37). 2'-PP was purified by chromatography and recrystalization from ethylacetate (37): melting point 171-172°C, 1H-NMR (d6-DMSO) 13.0 [singlet (s), 1H], 10.7 [broad singlet (brs), 1H], 9.2 (brs, 1H), 7.03 [doublet (d), J = 8.6 Hz, 2H], 6.64 (d, J = 8.4 Hz, 2H), 6.63 (dd, J = 1.2, 2.1 Hz, 1H), 2.77 (d, J = 7.6 Hz, 2H). 31P-NMR in D2O yielded a single peak at 4 parts per million comprising 98% of the phosphorus signal. 31P-NMR in DMSO yielded a single peak at 4.3 pulses/min.
Statistical analysis. Results are presented as means ± SE for all rats in the experimental group. Numbers of rats used are shown in the figures or described in RESULTS. Comparisons were made between untreated uremic rats and 2'-PP-treated uremic rats, using an unpaired Student's t-test. In some experiments, changes in untreated uremic control rats were compared as a function of time, using a paired Student's t-test. Significance values are shown in the figures.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
The effect of gavage on intestinal protein absorption and intestinal Ca2+ absorption was also examined to determine the specificity of 2'-PP for intestinal phosphate absorption and as a control for nonspecific intestinal malabsorption. Before the start of gavage, intestinal protein absorption was 92 ± 3% (n = 8 rats) in uremic rats and 94 ± 2% (n = 4 rats) in age-matched control rats with normal renal function. After 4 wk of gavage, protein absorption was 92 ± 3% in untreated uremic rats and 90 ± 4% in 2'-PP-treated rats. Intestinal Ca2+ absorption in uremic rats was 80 ± 6% (n = 24 rats) before the start of the experiment. Intestinal Ca2+ absorption in untreated uremic rats was 81 ± 5% (n = 8 rats) after 4 wk of treatment. Intestinal Ca2+ absorption in uremic rats treated with 2'-PP was 77 ± 5% (n = 16 rats) after 4 wk of treatment with 2'-PP.
The effect of uremia and 2'-PP on fractional excretion of phosphate (FEPi) was also examined. At the start of the experiment, FEPi of 5/6 NX rats was 18 ± 0.9% (n = 24 rats). FEPi of untreated 5/6 NX rats increased to 20.9 ± 1.9% (n = 8 rats) at the end of the 5-wk experiment (not significant compared with 5/6 NX rats at the beginning of the experiment). FEPi of 2'-PP-treated rats decreased to 7.8 ± 1.4% (n = 16 rats) at the end of the 5-wk experiment (P < 0.01).
Effect of 2'-PP on plasma Ca2+.
The effect of 25 µM 2'-PP on serum Ca2+ is shown in Fig. 2. 2'-PP did not significantly alter serum Ca2+. Serum Ca2+ in 5/6 NX rats was 10 mg/dl at the start of the experiment before treatment with 2'-PP. Serum Ca2+ in uremic rats treated with 2'-PP (, dashed line) did not significantly change (10.2 mg/dl) during the treatment with 2'-PP. Untreated uremic rats (
, solid line) had a 4.7% increase in serum Ca2+ during the experiment and were slightly hypercalcemic (serum Ca2+ of 11 vs. 10.2 mg/dl for 2'-PP-treated uremic rats and 10 mg/dl for age-matched control rats with normal renal function;
, solid line) at the end of the experiment.
|
The effect of 2'-PP on the Ca2+ x HPO4 product is shown in Fig. 3. The Ca2+ x HPO4 product in 2'-PP-treated rats (, solid line) decreased 28% over the first 2 wk of treatment and remained stable at
70% of the starting value during the remainder of the experiment. The Ca2+ x HPO4 product in untreated uremic control rats (
, dashed line) increased slowly over the course of the first 3 wk of the experiment. Shown for comparison are results from age-matched control rats (
, dashed line).
|
|
|
|
Urine protein. Urine protein increased in untreated uremic rats from 40 mg/24 h (40 ± 4 mg/24 h) at the start of the experiment to 80 mg/24 h (80 ± 10 mg/24 h) at the end of the experiment. Urine protein in 2'-PP-treated uremic rats decreased 56% over the course of the 5-wk experiment (17.5 ± 2.5 mg/24 h).
Effect of 2'-PP treatment on BBMV Na+-dependent phosphate uptake and 2'-PP inhibition of phosphate uptake. The effect of treatment with 2'-PP on small intestinal BBMV Na+-dependent phosphate uptake was examined to determine whether treatment with 2'-PP altered Na+-phosphate cotransporter activity or sensitivity to 2'-PP. Treatment with 2'-PP did not alter the IC50 for 2'-PP inhibition of Na+-dependent phosphate uptake into intestinal BBMV isolated from uremic rats (Table 2). The IC50 values for 2'-PP inhibition of Na+-dependent phosphate uptake into intestinal BBMV isolated from uremic rats were similar in 2'-PP-treated rats, untreated uremic rats, and age-matched control rats with normal renal function.
|
The effect of phosphate concentration on 2'-PP inhibition of Na+-dependent phosphate uptake into intestinal BBMV isolated from 2'-PP-treated rats is shown in Fig. 7. Figure 7 is a Wolff-Augustinin-Hofstee plot of the effect of phosphate concentration on 2'-PP inhibition of Na+-dependent phosphate uptake into intestinal BBMV isolated from 2'-PP-treated rats at 25 nM 2'-PP (, dashed line) and 100 nM 2'-PP (
, solid line). Phosphate uptake in the absence of 2'-PP (
, solid line) is shown for comparison. As a function of 2'-PP concentration, the lines were shifted to the left, consistent with competition between 2'-PP and phosphate on the Na+-phosphate cotransporter. The calculated Vmax (y-intercept) was unaffected by 2'-PP. The results of the effect of 2'-PP treatment on intestinal BBMV Na+-phosphate cotransporter activity and sensitivity to 2'-PP were consistent with previous results with rat intestinal BBMV (37). These results also indicate that 2'-PP did not alter Na+-phosphate cotransporter kinetics and suggest that the effect of 2'-PP on serum phosphate was not due to a nonspecific intestinal toxicity of 2'-PP.
|
|
|
Left ventriclar (LV) wall thickness was slightly greater in untreated uremic rats than in 2'-PP-treated uremic rats (3.25 ± 0.25 mm in untreated uremic rats vs. 4.25 ± 0.2 mm in 2'-PP-treated uremic rats). Left ventriclar hypertrophy (LVH), expressed as LV grams per kilogram body weight, was also elevated in untreated uremic rats. Values were 1.7 ± 0.05 LV g/kg body wt (n = 8) for untreated uremic rats and 1.49 ± 0.06 LV g/kg body wt (n = 8) for 2'-PP-treated uremic rats.
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
A phosphorylated derivative of phloretin, 2'-PP, has been shown to be a specific inhibitor of intestinal phosphate absorption in vitro (3739) and in vivo (37). Previous studies using intestinal (37, 38) and renal (39) BBMV and aged adult rats (37) indicated that 2'-PP is a specific inhibitor of NaPi-IIb with IC50 values of 40 nM in vitro and 12 µM in vivo. 2'-PP inhibition of renal phosphate reabsorption appears to be limited to inhibition of NaPi-Ia (39). These studies have been extended to the uremic rat.
The effect of 25 µM 2'-PP on renal function and the progression of renal failure over a 2-mo experimental and a 5-wk treatment period were examined. At the beginning of treatment with 2'-PP, rats were in moderately severe chronic renal failure (Table 1). This assignment was based on a comparison with literature values and the average of three separate determinations of serum PTH, serum phosphate, serum creatinine, urine osmolality, and creatinine clearance (5, 20, 43).
The effect of 2'-PP on serum phosphate is shown in Fig. 1. Daily gavage with 25 µM 2'-PP decreased serum phosphate in uremic rats 42 ± 1.6%. In comparison, serum phosphate in untreated uremic rats continued to increase during the 5-wk experimental treatment 17 ± 2%.
2'-PP did not alter total serum Ca2+ during the 5-wk experiment (Fig. 2). 2'-PP did increase ionizable Ca2+ 19% over the 5-wk experiment, which could account for some of the observed decrease in serum PTH. Decreased serum phosphate yielded a 35% decrease in the Ca2+ x Pi product (Fig. 3) over the 5-wk experiment.
Consistent with previous studies with low-phosphorus diets (25, 8, 16, 18, 2427, 4447) and 5/6 NX rats, reduced serum phosphate decreased serum PTH. Serum PTH in uremic rats treated with 2'-PP decreased from 180 to 42 pg/ml over the course of the 5-wk experiment. In the absence of 2'-PP, uremic rat serum PTH approximately doubled over the 5-wk experiment.
The effect of 2'-PP on the glomerular filtration rate was examined using creatinine clearance. In 2'-PP-treated 5/6 NX rats, creatinine clearance increased 58 ± 6%, and serum creatinine decreased to 0.34 mg/ml during the 5-wk experiment. Creatinine clearance in untreated uremic rats fell slightly to 2.3 ml·min1·kg body wt1.
The use of creatinine clearances in the examination of treatment efficacy has been questioned (22). Creatinine is not an ideal substance for the determination of renal function due to creatinine renal creatinine secretion. To confirm the effect of 2'-PP on creatinine clearance, urine osmolality, urine protein, renal morphology, and cardiac morphology were also examined.
Renal failure is associated with reduced urine osmolality, increased urine volume, and increased urine protein. Urine osmolality increased 120% in 2'-PP-treated uremic rats over the course of treatment. The effect of 2'-PP treatment on urine osmolality of uremic rats is consistent with a minimal change in water reabsorption and a minimal decrease in distal tubule and collecting duct function. Urine protein decreased 50% in 2'-PP-treated uremic rats during the 5-wk experiment. These results are consistent with recent studies showing reversal of protein-induced tubulointerstitial damage early in the development of proteinuria (19). There does not appear to be a causal relationship between phosphate and urine protein. There is a correlation between the severity of renal failure and the degree of proteinuria (16) and the severity of renal failure and the severity of hyperphosphatemia.
Renal failure is also associated with tubule and glomerular hypertrophy, inflammation, and fibrinosis. Cardiomyocyte apoptosis, cardiac ischemia, and hypertrophy of the left ventricle wall are associated with the later stages of renal failure (11, 28). Figure 8 demonstrates slight renal hypertrophy of the remnant kidney in untreated uremic rats. There was slight epithelial cell expansion and slight expansion of Bowman's space around the glomerulus. Approximately 20% of the tubules contained PAS-positive material in the lumen. Fibrinosis was found only around the poles where renal tissue was removed during surgery. 2'-PP-treated uremic rats had similar epithelial cell expansion and little expansion of Bowmans's space. Fewer than 10% of the tubules contained PAS-positive material.
The effect of 2'-PP treatment on renal histology is consistent with a delay in the progression of renal failure and not a reversal of renal hypertrophy. Before the start of 2'-PP treatment, rat remnant kidneys had increased in size 40%. 2'-PP treatment did not decrease kidney size but did appear to decrease plaque formation in tubule lumens and decrease the rate of extracellular matrix deposition and mesangial cell expansion. Based on the size of proximal tubule cells, 2'-PP treatment did not reverse tubule cell expansion. The absence of gross changes in rat kidney morphology is consistent with previous studies (34, 35).
Cardiac sections from untreated and 2'-PP-treated uremic rats were similar. There was no inflammation or evidence of ischemic damage. LV wall diameter was larger in untreated uremic rats than in 2'-PP-treated uremic rats. Expressed per kilogram rat body weight, LVH was 1.7 g/kg body wt in untreated uremic rats compared with 1.4 g/kg body wt in 2'-PP-treated uremic rats, suggesting moderate LVH in untreated uremic rats.
The time course of the change in serum phosphate correlated with the decrease in serum PTH and the decrease in Ca2+ x Pi product. A plot of the change in serum PTH vs. the change in serum phosphate was linear, with a correlation coefficient of 0.983. The excellent correlation between serum phosphate and serum PTH suggests that the 2'-PP-mediated decrease in serum phosphate resulted in a similar decrease in serum PTH. A similar plot of the change in creatinine clearance vs. the change in serum phosphate was also linear, with a correlation coefficient of 0.91. These results are consistent with previous studies examining the effect of reduced dietary phosphorus on serum phosphate and renal function (4).
The mechanism responsible for the effect of reduced serum phosphate on serum PTH remains unclear. The effect of 2'-PP on ionized Ca2+, the parathyroid gland regulator, was 11%. It is unlikely that the 11% increase in ionizable Ca2+ was responsible for the reduced serum PTH. Reduced parathyroid gland responsiveness to serum Ca2+ is a hallmark of chronic renal failure. An effect of serum phosphate on parathyroid gland growth and PTH synthesis has been suggested (1, 20, 25, 33, 45, 46). The mechanism responsible for the effect of reduced serum phosphate on creatinine clearance and urine osmolality may be related to the decrease in urine protein (16), reduced Ca2+ retention in the proximal tubules, and tubule proteinase activity (42).
The mechanism responsible for reduced serum PTH and serum phosphate in uremic rats treated with 2'-PP appeared to be the result of inhibition of intestinal phosphate absorption at the intestinal Na+-phosphate cotransporter. Na+-dependent phosphate uptake into intestinal BBMV isolated from uremic rats, uremic rats treated with 2'-PP, and age-matched control rats with normal renal function was similar. The three study groups had similar IC50 values for 2'-PP inhibition of Na+-dependent phosphate uptake into intestinal BBMV and similar Km values for phosphate (Table 2). The absence of an effect of 2'-PP treatment on intestinal Na+-dependent phosphate uptake into intestinal BBMV indicates that the effect of 2'-PP on serum phosphate was not the result of nonspecific intestinal toxicity reducing serum phosphate.
Na+-dependent phosphate uptake into intestinal BBMV isolated from 2'-PP-treated uremic rats retained 2'-PP sensitivity and phosphate dependence similar to that seen with intestinal BBMV isolated from adult rats (37). 2'-PP inhibition of Na+-dependent phosphate uptake into intestinal BBMV isolated from 2'-PP-treated uremic rats at variable phosphate concentrations (Fig. 7) indicates that 2'-PP and phosphate compete for the Na+-phosphate cotransporter. These results are similar to results from isolated rat, rabbit, and human BBMV and suggest that the mechanism of 2'-PP inhibition of intestinal phosphate absorption was inhibition of the intestinal Na+-phosphate cotransporter and was similar to the effect of 2'-PP on Na+-dependent phosphate uptake into intestinal BBMV in vitro.
The results indicate that 2'-PP is an effective treatment for hyperphosphatemia and secondary hyperparathyroidism in the remnant kidney rat model of chronic renal failure. Based on the increase in creatinine clearance, increased urine osmolality, and decreased urine protein, 2'-PP treatment of uremic rats appeared to improve renal function over the course of the 5-wk experimental treatment. Inhibition of intestinal phosphate absorption was as effective a method of reducing serum phosphate as very-low-phosphorus diets (0.02 g phosphorus/100 g rat chow).
![]() |
ACKNOWLEDGMENTS |
---|
![]() |
FOOTNOTES |
---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Visit Other APS Journals Online |